SEC Form 4 · accession 0001209191-17-044998
INNOVATE BIOPHARMACEUTICALS, INC. · INNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven C Barre
Director
Period of report
May 31, 2017
Accepted (ET)
Jul 13, 2017 · 1:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551986
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 31, 2017 | A | 15,000 | $0.00 | A | 30,000 | D | |
| Common StockF1,F2 | Jul 11, 2017 | A | 10,000 | $0.00 | A | 40,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Grant of restricted common stock under Issuer's 2012 Omnibus Incentive Plan. Such shares are part of Reporting Person's compensation as a director of Issuer.
- F2Shares vest six months from date of grant. Vesting may be accelerated upon a change of control.